News | August 25, 2025
GSK forays into oncology in India with Jemperli and Zejula
The company is bringing precision therapies for gynaecological cancers
The company is bringing precision therapies for gynaecological cancers
The company has improved access to quality healthcare for seniors across both urban and rural areas
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
